What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?

Michaela J. Higgins, Nancy E. Davidson

Research output: Contribution to journalArticle

Abstract

The role of ovarian suppression/ablation (OS/OA) in premenopausal women with hormone receptor-positive breast cancer has been evolving for more than a century. It is clear that OS/OA is an effective adjuvant therapy for these women, but despite numerous studies enrolling thousands of women, many unanswered questions remain. In particular, a major question is whether additional benefit is gained with combination treatment comprising luteinizing hormone-releasing hormone (LH-RH) agonists and tamoxifen over tamoxifen alone. Ongoing trials also are assessing the coupling of aromatase inhibitors (traditionally contraindicated in these patients because of paradoxic stimulation of estrogen production) and LH-RH agonists. Any potential disease-free or overall survival advantage of combination treatment must be balanced against a possible increase in adverse effects and impairment of quality of life. This review focuses on new data on how to incorporate OS/OA into the rational treatment of this challenging patient population.

Original languageEnglish (US)
Pages (from-to)45-50
Number of pages6
JournalCurrent Oncology Reports
Volume11
Issue number1
StatePublished - Jan 2009

Fingerprint

Breast Neoplasms
Tamoxifen
Gonadotropin-Releasing Hormone
Aromatase Inhibitors
Therapeutics
Estrogens
Quality of Life
Hormones
Survival
Population

ASJC Scopus subject areas

  • Oncology

Cite this

What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? / Higgins, Michaela J.; Davidson, Nancy E.

In: Current Oncology Reports, Vol. 11, No. 1, 01.2009, p. 45-50.

Research output: Contribution to journalArticle

@article{660b9ea04ac841f4bd226e6e1df79d91,
title = "What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?",
abstract = "The role of ovarian suppression/ablation (OS/OA) in premenopausal women with hormone receptor-positive breast cancer has been evolving for more than a century. It is clear that OS/OA is an effective adjuvant therapy for these women, but despite numerous studies enrolling thousands of women, many unanswered questions remain. In particular, a major question is whether additional benefit is gained with combination treatment comprising luteinizing hormone-releasing hormone (LH-RH) agonists and tamoxifen over tamoxifen alone. Ongoing trials also are assessing the coupling of aromatase inhibitors (traditionally contraindicated in these patients because of paradoxic stimulation of estrogen production) and LH-RH agonists. Any potential disease-free or overall survival advantage of combination treatment must be balanced against a possible increase in adverse effects and impairment of quality of life. This review focuses on new data on how to incorporate OS/OA into the rational treatment of this challenging patient population.",
author = "Higgins, {Michaela J.} and Davidson, {Nancy E.}",
year = "2009",
month = "1",
language = "English (US)",
volume = "11",
pages = "45--50",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?

AU - Higgins, Michaela J.

AU - Davidson, Nancy E.

PY - 2009/1

Y1 - 2009/1

N2 - The role of ovarian suppression/ablation (OS/OA) in premenopausal women with hormone receptor-positive breast cancer has been evolving for more than a century. It is clear that OS/OA is an effective adjuvant therapy for these women, but despite numerous studies enrolling thousands of women, many unanswered questions remain. In particular, a major question is whether additional benefit is gained with combination treatment comprising luteinizing hormone-releasing hormone (LH-RH) agonists and tamoxifen over tamoxifen alone. Ongoing trials also are assessing the coupling of aromatase inhibitors (traditionally contraindicated in these patients because of paradoxic stimulation of estrogen production) and LH-RH agonists. Any potential disease-free or overall survival advantage of combination treatment must be balanced against a possible increase in adverse effects and impairment of quality of life. This review focuses on new data on how to incorporate OS/OA into the rational treatment of this challenging patient population.

AB - The role of ovarian suppression/ablation (OS/OA) in premenopausal women with hormone receptor-positive breast cancer has been evolving for more than a century. It is clear that OS/OA is an effective adjuvant therapy for these women, but despite numerous studies enrolling thousands of women, many unanswered questions remain. In particular, a major question is whether additional benefit is gained with combination treatment comprising luteinizing hormone-releasing hormone (LH-RH) agonists and tamoxifen over tamoxifen alone. Ongoing trials also are assessing the coupling of aromatase inhibitors (traditionally contraindicated in these patients because of paradoxic stimulation of estrogen production) and LH-RH agonists. Any potential disease-free or overall survival advantage of combination treatment must be balanced against a possible increase in adverse effects and impairment of quality of life. This review focuses on new data on how to incorporate OS/OA into the rational treatment of this challenging patient population.

UR - http://www.scopus.com/inward/record.url?scp=63149118048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63149118048&partnerID=8YFLogxK

M3 - Article

C2 - 19080741

AN - SCOPUS:63149118048

VL - 11

SP - 45

EP - 50

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 1

ER -